Sign-up for our monthly newsletter!

Sign-up for the M&A Perspective Newsletter!

Sign-up for the Arbitration Case Alert Newsletter!

 
Deals & Cases

Schellenberg Wittmer advises Santhera Pharmaceuticals in exclusive License Agreement with Polyphor

15.02.2018 – Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for orphan and other diseases with high unmet medical needs. On 15 January 2018, Santhera Pharmaceuticals announced that it had entered into an agreement with Polyphor Ltd. for POL6014, a clinical stage selective inhibitor of human neutrophil elastase with the potential to treat cystic fibrosis (CF) and other pulmonary diseases.

Under the agreement, Santhera obtains the worldwide, exclusive rights to develop and commercialize POL6014, for an initial payment of CHF 6.5 million and additional cash payments of up to CHF 121 million contingent to future development, regulatory and particularly sales milestones.

Schellenberg Wittmer is advising Santhera Pharmaceuticals on this matter.

The team consists of Philipp Groz (IP / Life Sciences), Pascal Hubli (Corporate/M&A), Michael Nordin and Petra Hess (both Tax).